CoChat
Sign Up
Cited by 35Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia ResearchMultiple Sclerosis Research Studies

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Hungria, Vania, Robak, Paweł, Hus, Marek, Zherebtsova, Vera, Ward, Christopher, Ho, P Joy, Hájek, Roman, Kim, Kihyun +33 more·2025·The Lancet Oncology
DOI 10.1016/s1470-2045(25)00330-4
Open this paper in CoChat — free account

Abstract

Background In the primary (first interim) analysis of the DREAMM-7 trial (median follow-up 28·2 months), belantamab mafodotin, bortezomib, and dexamethasone (BVd) showed a statistically significant and clinically meaningful progression-free survival benefit versus daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma (RRMM) after at least one line of therapy. The aim of this study is to report overall survival from the second interim analysis, with extended follow-up. Methods In the ongoing global, open-label, randomised, phase 3 DREAMM-7 trial done at 142 study centres (research facilities, hospitals, and institutions) in 20 countries across North America, South America, Europe, and the Asia-Pacific region, eligible patients were aged at least 18 years and had confirmed multiple myeloma (according to International Myeloma Working Group criteria), an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and progression on or after at least one previous line of therapy. Patients were randomly assigned (1:1) by use of a central interactive response technology system to receive BVd, which comprised belantamab mafodotin 2·5 mg/kg intravenously every 3 weeks plus bortezomib 1·3 mg/m 2 subcutaneously (twice weekly in 21-day cycles, for up to eight cycles) plus dexamethasone 20 mg orally or intravenously (on the day of, and after, bortezomib; for up to eight cycles), or DVd, which comprised daratumumab 16 mg/kg intravenously (21-day cycles; once weekly in cycles 1-3, every 3 weeks in cycles 4-8, and every 4 weeks in cycle 9 and beyond) plus bortezomib and dexamethasone; bortezomib and dexamethasone doses and schedules were the same as those in the BVd group. Randomisation was stratified by number of previous lines of therapy, previous bortezomib, and Revised International Staging System stage. Treatment assignments were unmasked for study personnel and patients; however, they were masked to the independent review committee. Patients received treatment until progressive disease, death, unacceptable toxicity, withdrawal of consent, or loss to follow-up, whichever occurred first. The primary endpoint was progression-free survival; key secondary endpoints were overall survival, minimal residual disease negativity in patients with a complete response or better, duration of response to treatment, and safety. Analysis of efficacy endpoints was based on assessments in all patients who were randomly assigned (ie, the intention-to-treat population). The safety population included all randomly assigned patients who received one or more doses of study treatment. This trial is registered with ClinicalTrials.gov, NCT04246047, and is ongoing. Findings From May 7, 2020, to June 28, 2021, of 623 patients assessed for eligibility, 494 were randomly assigned to receive BVd (n=243) or DVd (n=251); 272 (55%) were male, and 409 (83%) were White. The median age of the patients was 64·5 years (IQR 57·0-71·0). At the updated data cutoff (Oct 7, 2024) and median follow-up (39·4 months [IQR 14·6-42·9]), early, sustained, and significant overall survival benefit was observed with BVd versus DVd. Median overall survival was not reached (NR; 95% CI NR-NR) with BVd and NR (41·0 months-NR) with DVd (hazard ratio [HR] 0·58; 95% CI 0·43-0·79; p=0·0002). BVd versus DVd led to greater than double the minimal residual disease-negativity rates in patients with a complete response or better (25% [95% CI 19·8%-31·0%] vs 10% [6·9%-14·8%]) and median duration of response (40·8 months [95% CI 30·5 months-NR] vs 17·8 months [13·8-23·6]). Analysis of progression-free survival 2 showed that the treatment benefit favouring BVd versus DVd was maintained following subsequent antimyeloma therapy; median progression-free survival 2 was NR with BVd (95% CI 45·6-NR) versus 33·4 months (95% CI 26·7-44·9) with DVd (HR, 0·59; 95% CI, 0·45-0·77). The most common grade 3 or 4 adverse event was thrombocytopenia (135 [56%] of 242 with BVd vs 87 [35%] of 246 with DVd). Serious adverse events occurred in 129 (53%) of 242 patients receiving BVd and 94 (38%) of 246 patients receiving DVd; the most common events were pneumonia (29 [12%] vs 11 [4%]), pyrexia (12 [5%] vs 10 [4%]), and COVID-19 (11 [5%] vs 10 [4%]). Treatment-related serious adverse events that led to death occurred in seven (3%) of 242 patients receiving BVd (pneumonia [n=4], gastrointestinal haemorrhage [n=1], subdural haemorrhage [n=1], or mesenteric vessel thrombosis [n=1]) and two (1%) of 246 receiving DVd (COVID-19 [n=2]). Interpretation DREAMM-7 showed significant and clinically meaningful overall survival, progression-free survival, minimal residual disease negativity, and duration of response benefits with BVd versus DVd. BVd could be a new standard of care for RRMM. Funding GSK.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(25)00330-4

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Belantamab mafodotin has demonstrated improved progression-free and overall survival in early-line relapsed/refractory multiple myeloma.

    “Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27”

    From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [27]

Cites

Flagged first, then by citations

2 of the 31 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Hájek, R., Kim, K., Grosicki, S., Sia, H., Bryant, A., Pitombeira de Lacerda, M., Martinez, G. A., Sureda Balarí, A., Sandhu, I., Cerchione, C., Ganly, P., Dimopoulos, M. A., Fu, C., Garg, M., Abdallah, A.-O., Gatt, M. E., Oriol Rocafiguera, A., Cavo, M., Rifkin, R., Fujisaki, T., Mielnik, M., Ficek, J., Mantero, A., Pirooz, N., Varghese, S., Lee, J., McKeown, A., Rogers, R., Baig, H., Eccersley, L., Roy-Ghanta, S., Mukhopadhyay, P., Nielsen, J., Opalinska, J., & Mateos, M.-V.
Affiliations
  • Royal Prince Alfred Hospital (AU)
  • University of Ostrava (CZ)
  • Medical University of Silesia (PL)
  • Liverpool Hospital (AU)
  • Cross Cancer Institute (CA)
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
  • Christchurch Hospital (NZ)
  • Korea University (KR)
  • First Affiliated Hospital of Soochow University (CN)
  • University Hospitals of Leicester NHS Trust (GB)
  • University of Kansas (US)
  • Hebrew University of Jerusalem (IL)
  • Rocky Mountain Cancer Centers (US)
  • Matsuyama Red Cross Hospital (JP)
  • GlaxoSmithKline (United States) (US)
  • GlaxoSmithKline (United Kingdom) (GB)
  • GlaxoSmithKline (Canada) (CA)
  • Instituto de Investigación Biomédica de Salamanca (ES)
Corresponding author
Mateos, María-Victoria
ORCID
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2025-08
Volume
26
Issue
8
Pages
1067-1080
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(25)00330-4
OpenAlex
W4412461073
Semantic Scholar
277e318022977221ce84a7f9768327f6f2541295
Cited by
35
References
31
Citations by year
2026: 29 · 2025: 6
FWCI
25.69
Type
journal article
Language
en
Update notices
erratum (2025-10-01)
Open access
closed
Licence
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (acceptedVersion)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
Keywords
belantamab mafodotin, relapsed/refractory multiple myeloma, bortezomib, dexamethasone, daratumumab, overall survival, progression-free survival, minimal residual disease negativity, duration of response, CAR T-cell therapy, BCMA, BCMA-CD3 bispecific antibody
MeSH terms
Bortezomib, Progression-Free Survival, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review